- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Morphosys AG O.N. (MORG)
Real-time derived
Currency in EUR
Disclaimer
67.375
+0.125(+0.19%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
67.375
67.375
52 wk Range
14.520
69.750
MORG Scorecard
Full Analysis
Stock generally trades with low price volatility
Morphosys AG O.N. stock price live, this page displays ETR MORG stock exchange data. View the MORG premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Morphosys AG O.N. real time stock price chart below.
What Is the Morphosys AG O.N. Stock Price Today?
The Morphosys AG O.N. stock price today is 67.375.
What Is the Stock Symbol for Morphosys AG O.N.?
The stock ticker symbol for Morphosys AG O.N. is MORG.
Is MORG the Same as $MORG?
$MORG is a common way to refer to the Morphosys AG O.N. ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Morphosys AG O.N. Trade On?
Morphosys AG O.N. is listed and trades on the Xetra stock exchange.
Is Morphosys AG O.N. a Good Stock to Buy?
Determining whether Morphosys AG O.N.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Morphosys AG O.N. share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MORG quote. (ISIN: DE0006632003)
What Is the Morphosys AG O.N. Stock Price Today?
The Morphosys AG O.N. stock price today is 67.375.
What Is the Stock Symbol for Morphosys AG O.N.?
The stock ticker symbol for Morphosys AG O.N. is MORG.
Is MORG the Same as $MORG?
$MORG is a common way to refer to the Morphosys AG O.N. ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Morphosys AG O.N. Trade On?
Morphosys AG O.N. is listed and trades on the Xetra stock exchange.
Is Morphosys AG O.N. a Good Stock to Buy?
Determining whether Morphosys AG O.N.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Morphosys AG O.N. share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MORG quote. (ISIN: DE0006632003)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
67.37567.375
52 wk Range
14.52069.750
UnlockMORG Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Short term obligations exceed liquid assets
Morphosys AG O.N. Company Profile
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.
Compare MORG to Peers and Sector
Metrics to compare | MORG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMORGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.4x | −2.0x | −0.6x | |
PEG Ratio | 0.01 | −0.06 | 0.00 | |
Price / Book | −9.7x | 2.6x | 2.6x | |
Price / LTM Sales | 10.5x | 5.4x | 3.2x | |
Upside (Analyst Target) | 1.1% | 192.2% | 44.2% | |
Fair Value Upside | Unlock | 6.6% | 7.9% | Unlock |
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.